• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

沙特阿拉伯神经肌肉与电诊断医学专家以及海湾合作委员会地区的神经肌肉专家关于重症肌无力诊断与管理的共识指南。

Consensus guidelines on the diagnosis and management of myasthenia gravis by the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine and neuromuscular specialists from the Gulf Cooperation Council region.

作者信息

Alshehri Ali Mohammed, Alanazy Mohammed H, Alabdali Majed, Abuzinadah Ahmad R, Alshareef Aysha, Abulaban Ahmad, AlRoughani Raed A, Abdulla Fatema Mohamed, Hassan Ali M A, Alhatou Mohammed Ibrahim, Almadani Abubaker, Alrukn Suhail Abdulla, Alsaadi Taoufik, Al Salti Abdullah Mohammed, Shatila Ahmed, Thakre Mona Chetan, Alyahya Mossaed, Alzahmi Fatmah, AlHajjar Lynn, Alsolaihim Alanood A, Alamro Mazen, Alotaibi Muteb Khidhran, Bushnag Areej Abdulrahman, Bamaga Ahmed K, Jumah Mohammed Al

机构信息

Neuroscience Center, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia.

Department of Internal Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

出版信息

Ther Adv Neurol Disord. 2025 Jun 27;18:17562864251346333. doi: 10.1177/17562864251346333. eCollection 2025.

DOI:10.1177/17562864251346333
PMID:40584517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12205206/
Abstract

The introduction of numerous therapeutic advancements in the management of myasthenia gravis (MG) may add difficulties in clinical decision-making, especially when no recommendations tailored to the local context are available. For this reason, the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine (SANEM) chapter of the Saudi Neurology Society launched an initiative to discuss and agree on issues related to the management of MG in the Gulf Cooperation Council (GCC) region. An expert panel from all GCC countries (Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Qatar, and Oman) was formed to develop practical recommendations using the Delphi method to facilitate the management approach of MG and enhance patient outcomes.

摘要

重症肌无力(MG)治疗方面众多进展的引入可能会给临床决策带来困难,尤其是在没有适合当地情况的建议时。因此,沙特神经病学协会的沙特阿拉伯神经肌肉与电诊断医学(SANEM)分会发起了一项倡议,以讨论并就海湾合作委员会(GCC)地区MG管理相关问题达成共识。来自所有海湾合作委员会国家(沙特阿拉伯、阿拉伯联合酋长国、巴林、科威特、卡塔尔和阿曼)的一个专家小组成立,采用德尔菲法制定实用建议,以促进MG的管理方法并改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/246ab94ea130/10.1177_17562864251346333-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/7a14d70a65cb/10.1177_17562864251346333-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/c9af952f6edc/10.1177_17562864251346333-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/f93d8ee3696f/10.1177_17562864251346333-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/246ab94ea130/10.1177_17562864251346333-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/7a14d70a65cb/10.1177_17562864251346333-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/c9af952f6edc/10.1177_17562864251346333-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/f93d8ee3696f/10.1177_17562864251346333-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eca4/12205206/246ab94ea130/10.1177_17562864251346333-fig4.jpg

相似文献

1
Consensus guidelines on the diagnosis and management of myasthenia gravis by the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine and neuromuscular specialists from the Gulf Cooperation Council region.沙特阿拉伯神经肌肉与电诊断医学专家以及海湾合作委员会地区的神经肌肉专家关于重症肌无力诊断与管理的共识指南。
Ther Adv Neurol Disord. 2025 Jun 27;18:17562864251346333. doi: 10.1177/17562864251346333. eCollection 2025.
2
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.评估ravulizumab或efgartigimod对重症肌无力症状的控制:两种不同治疗方法的患者体验评估
Curr Med Res Opin. 2025 May;41(5):817-827. doi: 10.1080/03007995.2025.2497906. Epub 2025 May 24.
3
Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED].证据报告:眼肌型重症肌无力的医学治疗(基于证据的综述):美国神经病学学会质量标准小组委员会报告[已退休]
Neurology. 2007 Jun 12;68(24):2144-9. doi: 10.1212/01.wnl.0000263481.14289.90. Epub 2007 Apr 25.
4
Human biomonitoring of environmental contaminants in Gulf Countries - current status and future directions.海湾国家环境污染物的人体生物监测——现状与未来方向。
Environ Res. 2023 Nov 1;236(Pt 1):116650. doi: 10.1016/j.envres.2023.116650. Epub 2023 Jul 20.
5
Medical and surgical treatment for ocular myasthenia.眼肌型重症肌无力的药物及手术治疗
Cochrane Database Syst Rev. 2006 Apr 19(2):CD005081. doi: 10.1002/14651858.CD005081.pub2.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Internet addiction in Gulf countries: A systematic review and meta-analysis.海湾国家的网络成瘾问题:系统评价和荟萃分析。
J Behav Addict. 2021 Sep 6;10(3):601-610. doi: 10.1556/2006.2021.00057.
8
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂(GLP-1 RAs)减肥效果的网状Meta分析的数量、质量及结果:一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
9
Intravenous immunoglobulin for myasthenia gravis.静脉注射免疫球蛋白治疗重症肌无力
Cochrane Database Syst Rev. 2003(2):CD002277. doi: 10.1002/14651858.CD002277.
10
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.

本文引用的文献

1
Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis.精准医学靶向治疗重症肌无力的自身免疫机制。
Front Immunol. 2024 Jun 6;15:1404191. doi: 10.3389/fimmu.2024.1404191. eCollection 2024.
2
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.在重症肌无力(PROMISE-MG)中,硫唑嘌呤和霉酚酸酯的疗效比较:一项前瞻性队列研究。
Lancet Neurol. 2024 Mar;23(3):267-276. doi: 10.1016/S1474-4422(24)00028-0.
3
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
瑞昔珠单抗治疗全身性重症肌无力。
NEJM Evid. 2022 May;1(5):EVIDoa2100066. doi: 10.1056/EVIDoa2100066. Epub 2022 Apr 26.
4
Guideline for the management of myasthenic syndromes.肌无力综合征管理指南。
Ther Adv Neurol Disord. 2023 Dec 26;16:17562864231213240. doi: 10.1177/17562864231213240. eCollection 2023.
5
Incidence and prevalence of neurological disorders in the United Arab Emirates: a systematic review.阿联酋神经障碍的发生率和流行率:一项系统综述。
BMC Neurol. 2023 Nov 3;23(1):396. doi: 10.1186/s12883-023-03446-6.
6
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.齐鲁单抗是一种人补体成分 5 的大环肽抑制剂,通过双重作用模式来阻止末端补体途径的激活。
Front Immunol. 2023 Aug 9;14:1213920. doi: 10.3389/fimmu.2023.1213920. eCollection 2023.
7
Myasthenic crisis.肌无力危象。
Muscle Nerve. 2023 Jul;68(1):8-19. doi: 10.1002/mus.27832. Epub 2023 Apr 28.
8
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.抗乙酰胆碱受体抗体阳性全身型重症肌无力成人患者使用拉那利尤单抗的长期疗效和安全性:III 期 CHAMPION MG 开放标签扩展研究结果。
J Neurol. 2023 Aug;270(8):3862-3875. doi: 10.1007/s00415-023-11699-x. Epub 2023 Apr 27.
9
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.在全身性重症肌无力患者中zilucoplan 的安全性和疗效(RAISE):一项随机、双盲、安慰剂对照、3 期研究。
Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7.
10
Novel Immunotherapies for Myasthenia Gravis.重症肌无力的新型免疫疗法
Immunotargets Ther. 2023 Apr 4;12:25-45. doi: 10.2147/ITT.S377056. eCollection 2023.